As cliché as it sounds, it’s been a very interesting start to the year over the past six months.
Looking back on the first half of 2021, we continued to see a strong market response to 2020’s pandemic-driven ride. In terms of the overall market, the
S&P 500 is up nearly 18.41% year-to-date, while the
Nasdaq is 14.84% higher over the same time.
Additionally, we have also see some major moves in the
InvestorPlace Best Stocks for 2021 contest since the end of the first quarter. Not a single ticker remains in the same position it was in at the end of Q1, and a most importantly, we have a new leader by a significant margin.
AFL hard men Hall of Infamy: Top 10 thugs
theroar.com.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theroar.com.au Daily Mail and Mail on Sunday newspapers.
Migrating swans returning to Iowa
globegazette.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globegazette.com Daily Mail and Mail on Sunday newspapers.
(NASDAQ:PRPO) announces that Mr. Ron Andrews has joined the company s Board of Directors. As the company continues to build its products division around commercializing the technologies it has developed (such as HemeScreen and IV-cell), having additional resources and experienced industry veterans to support management s goals is key to its success and ongoing growth.
Mr. Andrews brings a wealth of experience in the diagnostics world, and specifically in the areas of product development & commercialization. Some of Mr. Andrews past experiences includes Chief Commercial Officer at Roche Molecular; President of Genetic Science Division at Thermo Fisher Scientific; President of the Medical Sciences Venture at Life Technologies Corporation; and CEO of Clarient, which was acquired by GE Healthcare for $580M in 2010.